Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants
- Conditions
- DiphtheriaHepatitis BTetanusPertussisPoliomyelitis
- Interventions
- Biological: DTaP-IPV//PRP~T combined vaccine
- First Posted Date
- 2006-03-16
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 458
- Registration Number
- NCT00303316
Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis
- Conditions
- Joint Disease
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 590
- Registration Number
- NCT00303056
- Locations
- 🇵🇱
Administrative Office, Warszawa, Poland
Rasburicase in Tumor Lysis Syndrome
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 33
- Registration Number
- NCT00302653
- Locations
- 🇧🇷
Sanofi-aventis administrative office, São Paulo, Brazil
Mixed Antagonist of Serotonin for Claudication Optimal Therapy
- Conditions
- Intermittent Claudication
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2008-12-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 599
- Registration Number
- NCT00300339
- Locations
- 🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 542
- Registration Number
- NCT00299871
- Locations
- 🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine
VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt
- Conditions
- Metabolic Syndrome
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 254
- Registration Number
- NCT00299325
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, United Kingdom
Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors
- First Posted Date
- 2006-03-03
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 59
- Registration Number
- NCT00298675
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Insulin Glulisine in Type 1 Diabetes Mellitus
- Conditions
- Type 1 Diabetes Mellitus
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00297583
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 132
- Registration Number
- NCT00296816
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome
- Conditions
- Metabolic Syndrome x
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 216
- Registration Number
- NCT00296803
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States